Posts by Marc N. Wein, MD, PhD
-
Mass General Researchers Develop New Oral Compound for Osteoporosis Prevention and Treatment
Massachusetts General Hospital researchers have identified a new compound that increased bone formation and bone mass when given orally to mice. Their findings may lead to a new, more convenient therapy for the prevention and treatment of osteoporosis.
-
Novel Strategy Identified for Treating Osteoporosis
Cheng-Chia Tang, PhD, and Marc N. Wein, MD, PhD, of the Endocrine Unit, and colleagues demonstrated in a preclinical osteoporosis model that an oral drug, YKL-05–099, boosts bone formation and trabecular bone mass—and unlike current anabolic osteoporosis therapies, inhibits bone resorption.
Biography
Marc Wein is an Assistant Professor of Medicine at Harvard Medical School and an Associate Member of the Broad Institute. Marc received his BS and MS from Yale University, MD and PhD from Harvard Medical School, and was trained in Internal Medicine and Endocrinology at Massachusetts General Hospital where he currently runs his research laboratory and clinical practice. He has received research funding and awards from the NIH, American Society of Clinical Investigation, Harrington Discovery Institute, Endocrine Society, Stepping Strong Center for Trauma Innovation, and American Society of Bone and Mineral Research.
Endocrinology Division
The Endocrinology Division at Massachusetts General Hospital offers a comprehensive integrated program of clinical services for both primary and tertiary care of adults with endocrine disorders.